Clinical trial
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
NCT00235508 · Sumitomo Pharma America, Inc., Industry · Completed
Key facts
| NCT number | NCT00235508 |
|---|---|
| Title | Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder |
| Official title | The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder. |
| Lead sponsor | Sumitomo Pharma America, Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Insomnia, Generalized Anxiety Disorder |
| Intervention type | Drug |
| Interventions | Eszopiclone (Lunesta) |
| Enrollment | 420 |
| Start date | Jun 1, 2005 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Oct 10, 2005 |
| Last update posted | Feb 22, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: